• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    6/13/23 1:44:11 PM ET
    $AUMN
    $BBIG
    $BENF
    $BIOC
    Precious Metals
    Basic Materials
    Recreational Games/Products/Toys
    Consumer Discretionary
    Get the next $AUMN alert in real time by email

     

    On Tuesday, 32 companies reached new 52-week lows.

    Key Facts About Today's 52-Week Lows:

    • Vodafone Group (NASDAQ:VOD) is the largest company in terms of market cap to set a new 52-week low this morning.
    • The smallest company by market cap to set a new 52-week low was Nova Lifestyle (NASDAQ:NVFY).
    • OceanPal (NASDAQ:OP)'s stock made the biggest move downwards, diving 26.32% to reach a new 52-week low.
    • EBET (NASDAQ:EBET) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    On Tuesday, the following stocks hit new 52-week lows:

    • Vodafone Group (NASDAQ:VOD) stock hit a new 52-week low of $9.00. The stock was down 0.49% on the session.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) shares made a new 52-week low of $124.58 on Tuesday. The stock was up 0.31% for the day.
    • Indivior (NASDAQ:INDV) shares set a new 52-week low of $21.71. The stock traded down 2.99%.
    • Beneficient (NASDAQ:BENF) shares set a new 52-week low of $5.65. The stock traded down 11.77%.
    • Oxford Square Cap (NASDAQ:OXSQ) stock hit a yearly low of $2.69. The stock was down 0.44% for the day.
    • Alaunos Therapeutics (NASDAQ:TCRT) stock achieved a new 52-week low on Tuesday morning, hitting $0.45 and moving up 2.25%.
    • Mullen Automotive (NASDAQ:MULN) shares fell to $0.33 on Tuesday, setting a new 52-week low with a shift of down 12.62%.
    • Integra Resources (AMEX:ITRG) stock hit a new 52-week low of $0.95. The stock was down 0.21% on the session.
    • Powerbridge Technologies (NASDAQ:PBTS) stock hit a yearly low of $1.30. The stock was up 0.01% for the day.
    • Enochian BioSciences (NASDAQ:ENOB) shares hit a yearly low of $0.62. The stock was down 6.51% on the session.
    • Iridex (NASDAQ:IRIX) stock set a new 52-week low of $1.84 on Tuesday, moving up 3.17%.
    • Vinco Ventures (NASDAQ:BBIG) stock achieved a new 52-week low on Tuesday morning, hitting $1.88 and moving down 4.51%.
    • Golden Minerals (AMEX:AUMN) stock hit a new 52-week low of $2.04. The stock was down 7.17% on the session.
    • Precipio (NASDAQ:PRPO) shares were down 1.72% for the day, having made a 52-week low of $0.43.
    • Greenidge Generation Hldg (NASDAQ:GREE) stock set a new 52-week low of $1.55 on Tuesday, moving down 3.3%.
    • Tenon Medical (NASDAQ:TNON) stock hit a new 52-week low of $0.70. The stock was down 5.11% on the session.
    • Plus Therapeutics (NASDAQ:PSTV) shares moved down 1.29% on Tuesday to hit a new 52-week low of $3.02, drifting down 1.29%.
    • Cyxtera Technologies (NASDAQ:CYXT) shares hit a yearly low of $0.04. The stock was down 11.37% on the session.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares made a new 52-week low of $2.48 on Tuesday. The stock was down 3.7% for the day.
    • EBET (NASDAQ:EBET) shares set a new yearly low of $0.19 this morning. The stock was 0.0% (flat) on the session.
    • iMedia Brands (NASDAQ:IMBI) stock hit a new 52-week low of $0.16. The stock was down 7.8% on the session.
    • BiondVax Pharmaceuticals (NASDAQ:BVXV) shares fell to $1.29 on Tuesday, setting a new 52-week low with a shift of down 1.73%.
    • Greenlane Hldgs (NASDAQ:GNLN) shares hit a yearly low of $2.10. The stock was down 4.5% on the session.
    • OceanPal (NASDAQ:OP) stock achieved a new 52-week low on Tuesday morning, hitting $2.56 and moving down 26.32%.
    • Biocept (NASDAQ:BIOC) stock achieved a new 52-week low on Tuesday morning, hitting $1.76 and moving down 1.6%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $AUMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUMN
    $BBIG
    $BENF
    $BIOC

    CompanyDatePrice TargetRatingAnalyst
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Vodafone Group Plc
    $VOD
    1/7/2026Hold → Buy
    Berenberg
    Integra Resources Corp.
    $ITRG
    12/8/2025$5.75Buy
    Roth Capital
    Vodafone Group Plc
    $VOD
    12/8/2025Equal Weight → Overweight
    Barclays
    Jazz Pharmaceuticals plc
    $JAZZ
    11/24/2025$188.00Buy → Neutral
    UBS
    Vodafone Group Plc
    $VOD
    11/3/2025Neutral → Sell
    UBS
    Vodafone Group Plc
    $VOD
    10/21/2025$8.00Underperform
    BNP Paribas Exane
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    More analyst ratings

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,588 worth of shares (1,101 units at $1.44), increasing direct ownership by 0.99% to 112,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    1/29/26 3:58:25 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,898 worth of shares (1,300 units at $1.46), increasing direct ownership by 1% to 111,589 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    1/28/26 1:13:52 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

    BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first exp

    2/5/26 8:04:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra Announces US$55 Million Bought Deal Financing

    VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Integra Resources Corp. ("Integra" or the "Company") (TSXV:ITR, NYSE:ITRG) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc. as co-lead underwriters and joint bookrunners on behalf of a syndicate of underwriters (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a "bought deal" basis, 16,180,000 common shares of the Company (the "Common Shares") at a price of US$3.40 per Common Share (the "Issue Price") for gross proceeds of US$55,012,000 (the "Offering"). The Company has granted the Underwriters an over-allo

    2/4/26 5:07:07 PM ET
    $ITRG
    Precious Metals
    Basic Materials

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Vodafone PLC upgraded by Berenberg

    Berenberg upgraded Vodafone PLC from Hold to Buy

    1/7/26 1:20:32 PM ET
    $VOD
    Telecommunications Equipment
    Telecommunications

    Roth Capital initiated coverage on Integra Resources Corp. with a new price target

    Roth Capital initiated coverage of Integra Resources Corp. with a rating of Buy and set a new price target of $5.75

    12/8/25 8:34:44 AM ET
    $ITRG
    Precious Metals
    Basic Materials

    $AUMN
    $BBIG
    $BENF
    $BIOC
    SEC Filings

    View All

    Tenon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Tenon Medical, Inc. (0001560293) (Filer)

    2/6/26 4:11:35 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Vodafone Group Plc

    6-K - VODAFONE GROUP PUBLIC LTD CO (0000839923) (Filer)

    2/6/26 8:40:09 AM ET
    $VOD
    Telecommunications Equipment
    Telecommunications

    SEC Form 6-K filed by Vodafone Group Plc

    6-K - VODAFONE GROUP PUBLIC LTD CO (0000839923) (Filer)

    2/5/26 12:07:24 PM ET
    $VOD
    Telecommunications Equipment
    Telecommunications

    $AUMN
    $BBIG
    $BENF
    $BIOC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ip Jonathan Hue-Fay

    3 - Greenlane Holdings, Inc. (0001743745) (Issuer)

    2/4/26 4:55:45 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Chief Financial Officer Mulvihill Christian sold $2,506 worth of shares (1,958 units at $1.28), decreasing direct ownership by 2% to 95,451 units (SEC Form 4)

    4 - Greenidge Generation Holdings Inc. (0001844971) (Issuer)

    2/4/26 4:37:13 PM ET
    $GREE
    Finance: Consumer Services
    Finance

    President Irwin Dale sold $2,541 worth of shares (1,985 units at $1.28), decreasing direct ownership by 2% to 103,285 units (SEC Form 4)

    4 - Greenidge Generation Holdings Inc. (0001844971) (Issuer)

    2/4/26 4:36:54 PM ET
    $GREE
    Finance: Consumer Services
    Finance

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beneficient Appoints Peter T. Cangany Jr. as Chairman of the Board

    DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the "Board") has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee since 2019. He brings decades of leadership experience in financial reporting, accounting, and corporate governance within the financial services industry. Mr. Cangany retired as a partner

    12/17/25 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INTEGRA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 GOLD PRODUCTION RESULTS FROM FLORIDA CANYON MINE, ACHIEVING PRODUCTION GUIDANCE AND SIGNIFICANT CAPITAL REINVESTMENT

    VANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV:ITR, NYSE:ITRG) is pleased to provide an interim operational update for the fourth quarter ended December 31, 2025 (the "fourth quarter 2025" or "Q4 2025"). The Company plans to release its fourth quarter and full year 2025 financial results after market close on Tuesday, March 24, 2026, followed by a conference call hosted by senior management on Wednesday, March 25, 2026 at 11:00 AM Eastern Time / 8:00 AM Pacific Time. (All amounts in United States ("U.S.") dollars as at De

    1/26/26 4:30:00 PM ET
    $ITRG
    Precious Metals
    Basic Materials

    $AUMN
    $BBIG
    $BENF
    $BIOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:18:52 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:17:41 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by OceanPal Inc.

    SC 13D/A - OceanPal Inc. (0001869467) (Subject)

    12/2/24 4:13:58 PM ET
    $OP
    Marine Transportation
    Consumer Discretionary